"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. PLoS One. 2025; 20(6):e0325561.
-
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial). Sci Rep. 2025 Mar 22; 15(1):9882.
-
Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019. J Infect Dis. 2025 Mar 17; 231(3):677-683.
-
Predictors of seropositivity to SARS-CoV-2 among employees at a large urban medical center. BMC Public Health. 2024 10 09; 24(1):2754.
-
Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques. Gene Ther. 2025 Jan; 32(1):16-24.
-
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023 05; 12(10):11248-11253.
-
SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):e30.
-
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect Dis. 2022 05; 22(5):636-648.
-
Humoral responses to SARS-CoV-2 mRNA vaccines: Role of past infection. PLoS One. 2021; 16(11):e0259703.
-
Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening. HIV Clin Trials. 2014 Mar-Apr; 15(2):62-8.